ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2374

Characteristics, Treatment Responses and Prognosis in a Single Center Cohort of SLE Patients with Thrombocytopenia
Abstract Number: 1166

Characteristics, Treatments, and Outcomes of Patients with Dermatomyositis from Two Large, Nationwide US Cohorts
Abstract Number: 1444

Characterization and Comparison of MRI Findings in Axial Spondyloarthritis, Axial Psoriatic and Chronic Non-inflammatory Back Pain
Abstract Number: 2689

Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Abstract Number: 2308

Characterization of Damage in a Primary Sjogren’s Syndrome Cohort
Abstract Number: 1827

Characterization of Fibroblast Subpopulations and Their Cellular Local Environments in Systemic Sclerosis Using Imaging Mass Cytometry
Abstract Number: 1771

Characterization of Pathogenic Immune Mechanisms in Oligoarticular Juvenile Idiopathic Arthritis Applying Single-cell Transcriptomics and Proteomics
Abstract Number: 2436

Characterization of RO7507062, a CD19-Targeting T-Cell Bispecific Antibody (CD19TCB), and Design of Its Ongoing Phase 1 Trial in Systemic Lupus Erythematosus
Abstract Number: 2283

Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry
Abstract Number: 0337

Characterization of Statin Induced Myopathy in the Hospital Setting
Abstract Number: 1161

Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Abstract Number: 1585

Characterization of the Fecal Metabolome in Early Systemic Sclerosis
Abstract Number: 2502

Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease
Abstract Number: 0079

Characterization of the Tissue Resident Memorial T Cells in Autoimmune Arthritis: A Comparative Study of Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Number: 1848

Characterization of Treg Phenotype, Function and Its Transcriptome Signatures in Treatment-naïve Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].